

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 Jul 2026

### Effect of Fentanyl addition to Ketamin, Midazolam mixture in intravenous sedation of 2 to 6 years old uncooperative children

#### Protocol summary

##### Study aim

Addition of fentanyl to Ketamin-Midazolam-based intravenous sedation for 2-6 years old uncooperative dental patients

##### Design

Randomized cross over triple blind clinical trial

##### Settings and conduct

32 children referred to the pedodontics department of Shahid Beheshti University of Medical Sciences at the dental school between the ages of 2 and 6 years with the criteria mentioned for clinical trial will be selected. The medications are prepared by an anesthetist and administered by an anesthetic technician without notice of clinician and of the selected drug type. A randomized computerized list for allocation of patients is used in two groups of 1 or 2 drug regimens to eliminate the Carry over effect. Blood pressure cuff, pulsed oximeter, chest lid probes are used. Oxygen and Nitrous Oxide administered through a nasal cannula at a total rate of 3 liters per minute.

##### Participants/Inclusion and exclusion criteria

2 to 6 years old non-cooperative children (definitely negative at Frankl's scale) that at least two pediatric dentist have evaluated their lack of co-operation; patients do not have any systemic disease, contraindication in drug usage, mouth opening limitation, macroglossia and tonsillar hypertrophy . patients need at least 2 same treatment session with local anesthetics. patient do not have any respiratory infection and nasal obstruction in treatment session.

##### Intervention groups

Intervention group 1: In 1st session intravenous sedation with Ketamin, Midazolam. In 2nd session intravenous sedation with Fentanyl, Ketamin and Midazolam.  
Intervention group 2: In 1st session intravenous sedation with Fentanyl, Ketamin, Midazolam. In 2nd session intravenous sedation with Ketamin and Midazolam.

##### Main outcome variables

O2 saturation; Heart rate; Respiratory rate; Blood

pressure; Sleepiness, motion, cry and overall behavior according to Houpt sedation scale.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20140106016106N5**

Registration date: **2018-08-05, 1397/05/14**

Registration timing: **retrospective**

Last update: **2018-08-05, 1397/05/14**

Update count: **0**

##### Registration date

2018-08-05, 1397/05/14

##### Registrant information

##### Name

Ghassem Ansari

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2225 5958

##### Email address

drgansari@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2017-09-23, 1396/07/01

##### Expected recruitment end date

2018-02-24, 1396/12/05

##### Actual recruitment start date

2017-09-23, 1396/07/01

##### Actual recruitment end date

2018-04-25, 1397/02/05

## **Trial completion date**

empty

## **Scientific title**

Effect of Fentanyl addition to Ketamin, Midazolam mixture in intravenous sedation of 2 to 6 years old uncooperative children

## **Public title**

"Sedation with Fentanyl & Ketamin in pediatric dentistry"

## **Purpose**

Treatment

## **Inclusion/Exclusion criteria**

### **Inclusion criteria:**

2 to 6 year old non-cooperative children (definitely negative at Frankl's scale) that at least two pediatric dentist have evaluated their lack of co-operation At least 2 same treatment sessions with local anesthetics are required The patient is in the ASA I group.

### **Exclusion criteria:**

Patients with systemic diseases Any contraindication in drug use Any contraindication in sedation

## **Age**

From **2 years** old to **6 years** old

## **Gender**

Both

## **Phase**

3

## **Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

## **Sample size**

Target sample size: **32**

More than 1 sample in each individual

Number of samples in each individual: **2**

Each patient randomly receives intravenously Midazolam and Ketamine in a session and in other session Fentanyl, Ketamine and Midazolam.

Actual sample size reached: **32**

## **Randomization (investigator's opinion)**

Randomized

## **Randomization description**

Random numbers

## **Blinding (investigator's opinion)**

Triple blinded

## **Blinding description**

The patient's parents are acquainted with the research method and informed consent is obtained.

Patient, clinician and person that records behavioral effects.

## **Placebo**

Not used

## **Assignment**

Crossover

## **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### **1**

#### **Ethics committee**

##### **Name of ethics committee**

Ethics Committee in Biomedical Research, Research Institute of Dental Sciences

##### **Street address**

Office of Ethics, Research Institute for Dental Sciences, 5th floor, Dental school, Shahid Beheshti University of Medical Sciences, Student blvd, Evin

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

1983663113

##### **Approval date**

2017-08-07, 1396/05/16

##### **Ethics committee reference number**

IR.SBMU.RIDS.REC.1396.469

## **Health conditions studied**

### **1**

#### **Description of health condition studied**

Intravenous sedation in dentistry

#### **ICD-10 code**

#### **ICD-10 code description**

## **Primary outcomes**

### **1**

#### **Description**

O2 Saturation of blood

#### **Timepoint**

Recording O2 saturation at the baseline, anesthesia injection, 15 and 30 minutes after the start of treatment and at discharge of the patient

#### **Method of measurement**

Alborz Saadat hospital monitoring device

### **2**

#### **Description**

Heart rate

#### **Timepoint**

Recording Heart rate at the baseline, anesthesia injection, 15 and 30 minutes after the start of treatment and at discharge of the patient

#### **Method of measurement**

Alborz Saadat hospital monitoring device

### **3**

#### **Description**

Blood pressure

#### **Timepoint**

Recording Blood pressure at the baseline, anesthesia

injection, 15 and 30 minutes after the start of treatment and at discharge of the patient

**Method of measurement**

Alborz Saadat hospital monitoring device

**4**

**Description**

Respiratory rate

**Timepoint**

Recording respiratory rate at the baseline, anesthesia injection, 15 and 30 minutes after the start of treatment and at discharge of the patient

**Method of measurement**

Alborz Saadat hospital monitoring device

**5**

**Description**

Sleepiness scale

**Timepoint**

Anesthesia injection, 15 and 30 minutes after the start of treatment

**Method of measurement**

Houpt sedation scale

**6**

**Description**

Crying scale

**Timepoint**

Anesthesia injection, 15 and 30 minutes after the start of treatment

**Method of measurement**

Houpt sedation scale

**7**

**Description**

Motion scale

**Timepoint**

Anesthesia injection, 15 and 30 minutes after the start of treatment

**Method of measurement**

Houpt sedation scale

**8**

**Description**

Overall behavior

**Timepoint**

Anesthesia injection, 15 and 30 minutes after the start of treatment

**Method of measurement**

Houpt sedation scale

**Secondary outcomes**

**1**

**Description**

Parents' opinion about sedation session

**Timepoint**

24 hours after treatment

**Method of measurement**

Questionnaire

**2**

**Description**

Clinician opinion about treatment session

**Timepoint**

At the end of treatment session

**Method of measurement**

Questionnaire

**Intervention groups**

**1**

**Description**

Intervention group 1: In 1st session oral Midazolam suspension premedication (0.5 mg/kg) is administered half an hour before IV Ketamin (up to 2 mg/kg), 1 mg Midazolam and 0.1 mg Atropin injection. Then in 2nd session oral Midazolam suspension premedication (0.5 mg/kg) is administered half an hour before IV Fentanyl ( up to 1 mcg/kg), Midazolam 1 mg, Atropin 0.1 mg, Ketamin (up to 2 mg/kg) injection.

**Category**

Treatment - Drugs

**2**

**Description**

Intervention group 2: in 1st session oral Midazolam suspension premedication (0.5 mg/kg) is administered half an hour before IV Fentanyl ( up to 1 mcg/kg), Midazolam 1 mg, Atropin 0.1 mg and Ketamin (up to 2mg/kg) injection. Then in 2nd session oral Midazolam suspension premedication (0.5 mg/kg) is administered half an hour before IV Ketamin (up to 2 mg/kg), 1 mg Midazolam and 0.1 mg Atropin injection.

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Dental School, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Dr Ghassem Ansari

**Street address**

Dental School, Student's Blvd, Evin

**City**

Tehran

**Province**

Tehran

**Postal code**

1983963113

**Phone**

+98 21 2217 9421

**Fax**

+98 21 2225 5537

**Email**

drgansari@sbmu.ac.ir

## Sponsors / Funding sources

### 1

**Sponsor**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Afshin Zarghi

**Street address**

Office of Vice chancellor of research, 5th floor, Shahid Beheshti University of Medical Sciences, Daneshjoo blvd, Evin, Chamran Highway, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1983963113

**Phone**

+98 21 2243 9787

**Fax**

+98 21 2243 9981

**Email**

Zarghi@sbmu.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Ghassem Ansari

**Position**

PhD, Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Dentistry

**Street address**

Dental School, Students Blvd, Evin

**City**

Tehran

**Province**

Tehran

**Postal code**

1983963113

**Phone**

+98 21 2225 5958

**Fax**

+98 21 2225 5537

**Email**

drgansari@yahoo.com

**Web page address**

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Ghassem Ansari

**Position**

PhD, Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Dentistry

**Street address**

Dental School, Students Blvd, Evin

**City**

Tehran

**Province**

Tehran

**Postal code**

1983963113

**Phone**

+98 21 2225 5958

**Fax**

+98 21 2225 5537

**Email**

drgansari@yahoo.com

**Web page address**

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Shahid Beheshti University of Medical University

**Full name of responsible person**

Ghassem Ansari

**Position**

PhD, Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Dentistry

**Street address**

Dental School, Students Blvd, Evin

**City**

Tehran

**Province**

Tehran

**Postal code**

19863

**Phone**

+98 21 2225 5958

**Fax**

+98 21 2225 5537

**Email**

drgansari@yahoo.com

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Drug dose used and data results

**When the data will become available and for how long**

Accessibility 6 month after issuing results

**To whom data/document is available**

Researchers in medical or dental universities

**Under which criteria data/document could be used**

Statistical analysis and the use of data with the exact mention of the source is indispensable.

**From where data/document is obtainable**

Aii Rashidian, DDS, MS Email:

A\_rashidian@dentaliau.ac.ir Address: 1945883919, 8 unit, n 492, Pasdaran Ave., Tehran

**What processes are involved for a request to access data/document**

3 month after admission of request

**Comments**